References
- Druker B J, Tamura S, Buchduner E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996; 2: 561–566
- Kantarjian H, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C, Gambarcorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine 2002; 346: 645–652
- Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
- Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16: 2160–2161
- James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F -X. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003; 17: 978–979
- Yeo W, Zee B, Zhong S, Chan P KS, Wong W -L, Ho W M, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. British Journal of Cancer 2004; 90: 1306–1311
- Liang R, Lau G K, Kwong Y L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. Journal of Clinical Oncology 1999; 17: 394–398
- Lau G K, Leung Y H, Fong D Y, Au W Y, Kwong Y L, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324–2330
- Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leukemia & Lymphoma 2004; 45: 2349–2351
- Fabian M A, Biggs W H, 3rd, Treiber D K, Atteridge C E, Azimioara M D, Benedetti M G, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology 2005; 23: 329–336
- Dietz A B, Souan L, Knutson G J, Bulur P A, Litzow M R, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099
- Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo J V, Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339
- Mattiuzzi G N, Cortes J E, Talpaz M, Reuben J, Rios M B, Shan J, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clinical Cancer Research 2003; 9: 976–980
- Miyachi K, Ihara A, Hankins R W, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clinical Rheumatology 2003; 22: 329–332
- Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. Journal of Viral Hepatology 2004; 11: 141–147
- Chan H L, Chui A K, Lau W Y, Chan F K, Wong M L, Tse C H, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Journal of Medical Virology 2002; 68: 182–187